Table 2.
Univariate and multivariate analysis of factors associated with time to recurrence and overall survival in two independent cohorts of human HCC
| Cohort I (N = 260) | Time To Recurrence | Overall Survival | ||
|---|---|---|---|---|
| Clinical Variables | HR(95%CI) | P value | HR(95%CI) | P value |
| Univariate Analysis | ||||
| Age | 0.982(0.969–0.995) | 0.006 | 0.981(0.968–0.994) | 0.005 |
| Sex (male versus female) | 0.925(0.629–1.360) | 0.692 | 0.873(0.593–1.286) | 0.492 |
| Serum AFP (> 20 versus ≤ 20 ng/ml) | 1.349(0.943–1.931) | 0.102 | 1.405(0.970–2.036) | 0.072 |
| HBV infection (yes versus no) | 0.792(0.564–1.112) | 0.178 | 0.767(0.543–1.081) | 0.130 |
| Cirrhosis ( present versus absent) | 0.903(0.647–1.259) | 0.548 | 0.876(0.625–1.228) | 0.442 |
| Child–pugh score (B versus A) | 0.959(0.675–1.364) | 0.818 | 0.948(0.661–1.358) | 0.769 |
| Tumor number (multiple versus single) | 1.961(1.447–2.656) | < 0.001 | 2.048(1.503–2.791) | < 0.001 |
| Maximal tumor size (> 5 versus ≤ 5 cm) | 1.510(1.103–2.066) | 0.010 | 1.573(1.139–2.173) | 0.006 |
| Tumor encapsulation (absent versus present) | 3.422(2.507–4.669) | < 0.001 | 3.584(2.607–4.927) | < 0.001 |
| Microvascular invasion (present versus absent) | 3.111(2.280–4.245) | < 0.001 | 3.315(2.411–4.558) | < 0.001 |
| Tumor differentiation (III- IV versus I-II) | 3.155(2.243–4.437) | < 0.001 | 3.363(2.385–4.743) | < 0.001 |
| TNM stage (III versus I-II) | 6.680(4.741–9.414) | < 0.001 | 7.093(5.015–10.033) | < 0.001 |
| ETV1 (positive versus negative) | 2.059(1.519–2.792) | < 0.001 | 2.143(1.571–2.922) | < 0.001 |
| Multivariate analysis | ||||
| Tumor number (multiple versus single) | 1.441(0.925–2.247) | 0.106 | 1.530(0.973–2.406) | 0.066 |
| Maximal tumor size (> 5 versus ≤ 5 cm) | 1.417(0.966–2.078) | 0.075 | 1.465(0.986–2.175) | 0.059 |
| Tumor encapsulation (absent versus present) | 1.335(0.840–2.121) | 0.222 | 1.289(0.803–2.072) | 0.293 |
| Microvascular invasion (present versus absent) | 1.663(1.082–2.556) | 0.020 | 1.808(1.168–2.800) | 0.008 |
| Tumor differentiation (III- IV versus I-II) | 1.569(1.075–2.288) | 0.019 | 1.651(1.131–2.411) | 0.009 |
| TNM stage (III versus I-II) | 3.004(1.815–4.971) | < 0.001 | 3.004(1.796–5.026) | < 0.001 |
| ETV1 (positive versus negative) | 1.651(1.201–2.269) | 0.002 | 1.748(1.266–2.415) | 0.001 |
| Univariate Analysis | ||||
| Age | 0.992(0.977–1.008) | 0.327 | 0.988(0.972–1.003) | 0.117 |
| Sex (male versus female) | 1.080(0.695–1.678) | 0.732 | 0.987(0.645–1.510) | 0.952 |
| Serum AFP (> 20 versus ≤ 20 ng/ml) | 0.951(0.657–1.377) | 0.789 | 0.907(0.631–1.302) | 0.595 |
| HBV infection (yes versus no) | 2.203(1.380–3.519) | 0.001 | 2.305(1.444–3.679) | < 0.001 |
| Cirrhosis ( present versus absent) | 1.212(0.856–1.716) | 0.278 | 1.242(0.878–1.756) | 0.221 |
| Child–pugh score (B versus A) | 1.359(0.924–1.999) | 0.120 | 1.339(0.911–1.969) | 0.137 |
| Tumor number (multiple versus single) | 2.397(1.726–3.329) | < 0.001 | 2.391(1.724–3.316) | < 0.001 |
| Maximal tumor size (> 5 versus ≤ 5 cm) | 2.511(1.839–3.429) | < 0.001 | 2.317(1.705–3.151) | < 0.001 |
| Tumor encapsulation (absent versus present) | 3.058(2.239–4.177) | < 0.001 | 2.897(2.127–3.946) | < 0.001 |
| Microvascular invasion (present versus absent) | 2.213(1.624–3.016) | < 0.001 | 2.268(1.668–3.083) | < 0.001 |
| Tumor differentiation (III- IV versus I-II) | 3.539(2.561–4.890) | < 0.001 | 3.444(2.503–4.739) | < 0.001 |
| TNM stage (III versus I-II) | 5.481(3.913–7.675) | < 0.001 | 5.875(4.196–8.225) | < 0.001 |
| ETV1 (positive versus negative) | 2.218(1.629–3.020) | < 0.001 | 2.220(1.635–3.014) | < 0.001 |
| Multivariate analysis | ||||
| Tumor number (multiple versus single) | 1.272(0.852–1.898) | 0.239 | 1.236(0.823–1.857) | 0.307 |
| Maximal tumor size (> 5 versus ≤ 5 cm) | 1.146(0.790–1.662) | 0.473 | 1.013(0.704–1.456) | 0.946 |
| Tumor encapsulation (absent versus present) | 1.495(0.986–2.269) | 0.059 | 1.394(0.923–2.105) | 0.114 |
| Microvascular invasion (present versus absent) | 1.475(0.995–2.188) | 0.053 | 1.625(1.101–2.399) | 0.015 |
| Tumor differentiation (III- IV versus I-II) | 1.727(1.195–2.495) | 0.004 | 1.696(1.180–2.437) | 0.004 |
| TNM stage (III versus I-II) | 2.968(1.885–4.672) | < 0.001 | 3.518(2.230–5.550) | < 0.001 |
| ETV1 (positive versus negative) | 1.636(1.173–2.283) | 0.004 | 1.638(1.180–2.274) | 0.003 |